Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
165 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 141 | AmgenINDUSTRY | 33 | Jun 4, 2025 | clinicaltrials |
| NCT03473756 | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma(FORT-2) | completed | Phase 1 | 37 | BayerINDUSTRY | 8 | Apr 9, 2025 | clinicaltrials |
| NCT06172894 | PBMC-based Leukocyte Immunotherapy(PALINDROM) | completed | Phase 1 | 10 | invIOs GmbHINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03677141 | A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 117 | Hoffmann-La RocheINDUSTRY | 6 | Dec 18, 2024 | clinicaltrials |
| NCT04134936 | Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | completed | Phase 1 | 66 | MorphoSys AGINDUSTRY | 9 | Oct 16, 2024 | clinicaltrials |
| NCT06589609 | Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer | recruiting | Phase 1 | 12 | BlueSky Immunotherapies GmbHINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04770246 | TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations | terminated | Phase 1 | 17 | Taiho Oncology, Inc.INDUSTRY | 4 | Sep 4, 2024 | clinicaltrials |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors(CANFOUR) | completed | Phase 1 / Phase 2 | 167 | Cantargia ABINDUSTRY | 11 | Aug 22, 2024 | clinicaltrials |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611(MASTERKEY-318) | completed | Phase 1 / Phase 2 | 127 | AmgenINDUSTRY | 9 | Aug 6, 2024 | clinicaltrials |
| NCT02848443 | Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer | completed | Phase 1 | 78 | Institut de Recherches Internationales ServierOTHER | 7 | Jul 25, 2024 | clinicaltrials |
| NCT04822298 | Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer | terminated | Phase 1 | 3 | AmgenINDUSTRY | 3 | Jul 5, 2024 | clinicaltrials |
| NCT01796171 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma(LYMRIT-37-01) | completed | Phase 1 / Phase 2 | 191 | Nordic NanovectorINDUSTRY | 24 | Jun 21, 2024 | clinicaltrials |
| NCT04625907 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma(FaR-RMS) | recruiting | Phase 1 / Phase 2 | 1,672 | University of BirminghamOTHER | 20 | May 23, 2024 | clinicaltrials |
| NCT04524455 | Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL | completed | Phase 1 | 17 | AmgenINDUSTRY | 9 | Apr 8, 2024 | clinicaltrials |
| NCT03838042 | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies | recruiting | Phase 1 / Phase 2 | 91 | University Hospital HeidelbergOTHER | 7 | Feb 7, 2024 | clinicaltrials |
| NCT02718820 | Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 22 | Medical University of ViennaOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06155994 | 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours | completed | Phase 1 / Phase 2 | 12 | Medical University InnsbruckOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04168320 | SBRT-based PArtial Tumor Irradiation of HYpoxic Segment(SBRT-PATHY) | terminated | Phase 1 | 30 | Klinikum Klagenfurt am WörtherseeOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT04045613 | Derazantinib and Atezolizumab in Patients With Urothelial Cancer(FIDES-02) | completed | Phase 1 / Phase 2 | 95 | Basilea PharmaceuticaINDUSTRY | 14 | Oct 13, 2023 | clinicaltrials |
| NCT02592707 | Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs | terminated | Phase 1 / Phase 2 | 40 | IpsenINDUSTRY | 8 | Jul 19, 2023 | clinicaltrials |
| NCT04490512 | Study of FluBHPVE6E7 in HPV-16 Infected Women | completed | Phase 1 | 28 | BlueSky Immunotherapies GmbHINDUSTRY | 1 | Jun 26, 2023 | clinicaltrials |
| NCT03849105 | 131I-IPA and Concurrent XRT in Recurrent GBM(IPAX-1) | completed | Phase 1 / Phase 2 | 10 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 3 | Apr 14, 2023 | clinicaltrials |
| NCT04669067 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 18 | Telios Pharma, Inc.INDUSTRY | 8 | Feb 17, 2023 | clinicaltrials |
| NCT04042116 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | suspended | Phase 1 / Phase 2 | 227 | Clovis Oncology, Inc.INDUSTRY | 6 | Dec 20, 2022 | clinicaltrials |
| NCT05198752 | A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Stemirna TherapeuticsINDUSTRY | 2 | Oct 17, 2022 | clinicaltrials |
| NCT04658836 | Triamcinolone Levels in Cochlear Perilymph, Lateral Canal and CSF | completed | Phase 1 | 21 | Medical University of ViennaOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT03630159 | Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients(PORTIA) | completed | Phase 1 | 12 | Novartis PharmaceuticalsINDUSTRY | 3 | Aug 15, 2022 | clinicaltrials |
| NCT01884922 | Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults(VINILO) | completed | Phase 1 | 35 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 8 | May 27, 2022 | clinicaltrials |
| NCT02138955 | A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer | completed | Phase 1 / Phase 2 | 30 | SignPath Pharma, Inc.INDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT03000257 | A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | AbbVieINDUSTRY | 10 | Apr 14, 2022 | clinicaltrials |
| NCT00951457 | Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 / Phase 2 | 20 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT02462538 | Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL | terminated | Phase 1 / Phase 2 | 3 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT02299505 | Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 306 | Novartis PharmaceuticalsINDUSTRY | 24 | Feb 9, 2022 | clinicaltrials |
| NCT02947165 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 9 | Jan 31, 2022 | clinicaltrials |
| NCT01421186 | A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 91 | MorphoSys AGINDUSTRY | 2 | Nov 16, 2021 | clinicaltrials |
| NCT03291002 | Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC | unknown | Phase 1 | 98 | CureVacINDUSTRY | 5 | Nov 4, 2021 | clinicaltrials |
| NCT04418141 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 | completed | Phase 1 | 13 | Curon Biopharmaceutical (Australia) Co Pty LtdINDUSTRY | 1 | Oct 18, 2021 | clinicaltrials |
| NCT04882163 | Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | CelgeneINDUSTRY | 8 | Oct 5, 2021 | clinicaltrials |
| NCT02406742 | A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(ENHANCE) | completed | Phase 1 / Phase 2 | 47 | CelgeneINDUSTRY | 5 | Sep 20, 2021 | clinicaltrials |
| NCT02626000 | Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)(MASTERKEY232) | completed | Phase 1 | 36 | AmgenINDUSTRY | 11 | Sep 8, 2021 | clinicaltrials |
| NCT03136653 | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Molecular Partners AGINDUSTRY | 6 | Aug 25, 2021 | clinicaltrials |
| NCT00844233 | Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal Cancer(PARAGON-II) | completed | Phase 1 / Phase 2 | 40 | Boston Scientific CorporationINDUSTRY | 3 | Jul 21, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT01211483 | Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 222 | Daiichi SankyoINDUSTRY | 13 | Jun 16, 2021 | clinicaltrials |
| NCT01188681 | Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 79 | Aptevo TherapeuticsINDUSTRY | 5 | Jun 10, 2021 | clinicaltrials |
| NCT01409343 | TrasGEX™: Phase 1 Study in Cancer Patients | completed | Phase 1 | 37 | Glycotope GmbHINDUSTRY | 4 | May 7, 2021 | clinicaltrials |
| NCT02372006 | Trial of Afatinib in Pediatric Tumours | completed | Phase 1 / Phase 2 | 56 | Boehringer IngelheimINDUSTRY | 12 | Mar 4, 2021 | clinicaltrials |
| NCT00306202 | Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia | completed | Phase 1 | 63 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 26, 2021 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials